Latest & greatest articles for children

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on children or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on children and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for children

21. Paediatric multisystem inflammatory syndrome temporally associated with COVID-19

Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 1 Dear Colleagues We are writing to you in regards to a clinical alert published by the Royal College of Paediatrics and child Health on the 1 st of May 2020 highlighting a new COVID-19-associated paediatric hyper-inflammatory presentation (Guidance - Paediatric multisystem inflammatory syndrome temporally associated with COVID-19). Although COVID-19 respiratory presentation in children has been rare, several (...) children have recently presented to hospitals in the South Thames region with the described Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. Many of the children have been severely unwell at presentation requiring resuscitation and transfer to paediatric intensive care. As the anaesthetic team you may be asked to review and assist in their resuscitation and stabilisation. We thought it may be helpful to summarise some of the salient features of the presentation

2020 ICM Anaesthesia COVID-19

22. Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children

Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children Guidelines Hypertension Canada’s 2020 Evidence Review and Guidelines for the Management of Resistant Hypertension SwapnilHiremath,MD,MPH, a RuthSapir-Pichhadze,MD,MSc,PhD, b MerandaNakhla,MD,MSc, c JonathanY.Gabor,MD,MSc, d NadiaA.Khan,MD,MSc, e LauraM.Kuyper,MD, e MarcelRuzicka,MD,PhD, a SheldonW.Tobe,MD,MScH, f KarenTran,MD, e DoreenM.Rabi,MD (...) 25, 2019. After the discussions, the guidelines were further revised and ?nalized for anelectronic vote by all 81 members of the HCGC, with > 70% support required for approval of each new guideline. Guidelines for the diagnosis, assessment, prevention, and treatment of hyper- tension in adults and children are published separately. 10 Key Messages Resistant hypertension (RHT) is de?ned as blood pressure (BP) above target despite 3 or more BP- lowering drugs at optimal doses preferably including

2020 CPG Infobase

23. Rapid risk assessment: Paediatric inflammatory multisystem syndrome and SARS -CoV-2 infection in children

Rapid risk assessment: Paediatric inflammatory multisystem syndrome and SARS -CoV-2 infection in children Rapid risk assessment: Paediatric inflammatory multisystem syndrome and SARS -CoV-2 infection in children Global Navigation Other sites: European Centre for Disease Prevention and Control An agency of the European Union Main Navigation Secondary Navigation Search Search Search Search Rapid risk assessment: Paediatric inflammatory multisystem syndrome and SARS -CoV-2 infection in children (...) Rapid risk assessment: Paediatric inflammatory multisystem syndrome and SARS -CoV-2 infection in children Risk assessment 15 May 2020 Cite: European Centre for Disease Prevention and Control. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children – 15 May 2020. ECDC: Stockholm; 2020. Several countries affected by the coronavirus disease (COVID-19) pandemic recently reported cases of children that were hospitalised in intensive care due to a rare paediatric inflammatory

2020 European Centre for Disease Prevention and Control - Technical Guidance

24. Scientific Brief: Multisystem inflammatory syndrome in children and adolescents with COVID-19

, India. Lynne Mofenson, Elizabeth Glaser Pediatric AIDS Foundation, Washington DC, USA. Srinivas Murthy, BC Children’s Hospital, Vancouver, Canada. Pablo Rojo, Pediatric Infectious Diseases Unit, Hospital 12 de Octubre, Madrid, Spain. Calum Semple, Outbreak Medicine, University of Liverpool, UK. Louise Sigfrid, Centre for Tropical Medicine and Global Health, Oxford University, UK. Elizabeth Whittaker, Paediatric Infectious Diseases and Immunology, Imperial College, London, UK. Additional inputs Rosie (...) adults. Pediatr Pulmonol. 2020;55(5):1169-74. Epub 2020/03/07 Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. JAMA. 2020. Epub 2020/02/15 Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020;382(17):1663-5. Epub 2020/03/19 Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and Outcomes of Children With Coronavirus Disease 2019

2020 WHO Coronavirus disease (COVID-19) Pandemic

25. The use of prophylactic factor replacement for children and adults with Haemophilia A and B Full Text available with Trip Pro

will clearly differ, the International Society of Thrombosis and Haemostasis (ISTH) have defined the aims of prophylaxis in relation to joint health at onset : Primary prophylaxis Commences in early childhood at the latest before the second joint bleed or the age of 3 years, in the absence of documented joint disease, with the aim that the child reaches maturity with normal joints. , Secondary prophylaxis Commences after two or more joint bleeds, but before the onset of proven joint disease. It is likely (...) , compared to 38·2 (22·9–63·8) when treated OD. This supports the role of emicizumab for prophylaxis in PWSHA over the age of 12 years. The limited data in children with SHA and an inhibitor suggest that emicizumab will be efficacious in non‐inhibitor children. Caution is advised in this age group, who may be significantly more active than the older cohort and the paediatric group with inhibitors, any increase in bleed frequency will adversely impact on joint health and quality of life. There are even

2020 British Committee for Standards in Haematology

26. Covid-19 Transmission of the coronavirus by children

susceptibility? The Lancet Child & Adolescent Health. 3. Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World Journal of Pediatrics. 2020. 4. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72?314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42 (...) (like Sciensano, CSS/HGR, AFMPS/FAGG and SPF/FOD). 19 May 2020 COVID-19 – KCE CONTRIBUTIONS COVID-19 TRANSMISSION AND CHILDREN VICKY JESPERS 1 ? TABLE OF CONTENTS 1 SUMMARY 2 1.1 OBJECTIVES 2 1.2 METHODS 2 1.3 KEY RESULTS 2 1.4 CONCLUSION 2 2 PROBLEM DESCRIPTION 2 3 OBJECTIVE 3 4 METHODS 3 5 RESULTS 3 5.1 EPIDEMIOLOGICAL FEATURES AND CONTACT TRACING STUDIES 3 5.1.1 Household transmission 3 5.1.2 Child onward transmission 4 5.1.3 Epidemiological data from Sweden - example 4 5.1.4 Epidemiological data

2020 Belgian Health Care Knowledge Centre

27. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children

a number of seriously ill children presenting with signs of circulatory shock and hyperinflammatory state, with features consistent with toxic shock or KD (Table 1). Some of the tested children also were positive for SARS-CoV-2 infection. A case of classic KD with concurrent COVID-19 had already been reported on 7 April in the United States [3]. On 1 May, the Royal College of Paediatrics and Child Health published guidance on the clinical management of children with a presentation of paediatric (...) children accounted for less than 1% of all reported cases in China in early analyses [36,37]. Recent data from the US showed that 5.7%–20% of paediatric cases were hospitalised, a majority of them infants [39]. A recent study from Italy, involving 11 exclusively paediatric hospitals and 51 paediatric units across Italy, showed that hospital admission was inversely related to age (p?

2020 ICM Anaesthesia COVID-19

28. Pediatric Endoscopy in the Era of Coronavirus Disease 2019: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper

that all pediatric Received April 7, 2020; accepted April 8, 2020. From the Division of Gastroenterology, Hepatology and Nutrition and the Research and Learning Institutes, Hospital for Sick Children, Depart- ment of Paediatrics and the Wilson Centre, University of Toronto, Toronto,Canada,the y SectionofPediatricGastroenterology,Hepatology and Nutrition, Baylor College of Medicine, Houston, TX, and the z Department of Pediatrics, Section of Gastroenterology, Hepatology, and Nutrition, Medical College (...) , McGill University, Montreal, QC, Canada; Jane Alookaran, MD, University of Texas Health Science Center, Houston, TX; Ayesha S. Baig, MD, University of Rochester, New York, NY; Tavleen Bhatia, MD, Geisinger Commonwealth School of Medicine, Scranton, PA; Samuel Bitton, MD, Cohen Children’s Medical Center of New York, New Hyde Park, NY; Herbert Brill, MD, MBA, Department of Pediatrics, McMaster Children’s Hospital, Hamilton,ON,Canada;NicholasJ.Carman,MBBS,Children’sHospital ofEasternOntario,Ottawa

2020 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

29. Interventions to Prevent Illicit and Nonmedical Drug Use in Children, Adolescents, and Young Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Full Text available with Trip Pro

Interventions to Prevent Illicit and Nonmedical Drug Use in Children, Adolescents, and Young Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Illicit and nonmedical (use in ways other than instructed) drug use is common in adolescents and young adults and increases the risk of harmful outcomes such as injuries, violence, and poorer academic performance.To review the benefits and harms of interventions to prevent illicit and nonmedical drug use (...) in children, adolescents, and young adults to inform the US Preventive Services Task Force.MEDLINE, PubMED, PsycINFO, and the Cochrane Central Register of Controlled Trials (January 1, 2013, to January 31, 2019 [children and adolescents]; January 1, 1992, to January 31, 2019 [young adults <25 years]); surveillance through March 20, 2020.Clinical trials of behavioral counseling interventions to prevent initiation of illicit and nonmedical drug use among young people.Critical appraisal was completed

2020 JAMA

30. Primary Care-Based Interventions to Prevent Illicit Drug Use in Children, Adolescents, and Young Adults: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Primary Care-Based Interventions to Prevent Illicit Drug Use in Children, Adolescents, and Young Adults: US Preventive Services Task Force Recommendation Statement. In 2017, an estimated 7.9% of persons aged 12 to 17 years reported illicit drug use in the past month, and an estimated 50% of adolescents in the US had used an illicit drug by the time they graduated from high school. Young adults aged 18 to 25 years have a higher rate of current illicit drug use, with an estimated 23.2% currently (...) using illicit drugs. Illicit drug use is associated with many negative health, social, and economic consequences and is a significant contributor to 3 of the leading causes of death among young persons (aged 10-24 years): unintentional injuries including motor vehicle crashes, suicide, and homicide.To update its 2014 recommendation, the USPSTF commissioned a review of the evidence on the potential benefits and harms of interventions to prevent illicit drug use in children, adolescents, and young

2020 JAMA

31. Urinary tract infections in children. (Abstract)

Urinary tract infections in children. Urinary tract infections (UTIs) in children are among the most common bacterial infections in childhood. They are equally common in boys and girls during the first year of life and become more common in girls after the first year of life. Dividing UTIs into three categories; febrile upper UTI (acute pyelonephritis), lower UTI (cystitis), and asymptomatic bacteriuria, is useful for numerous reasons, mainly because it helps to understand the pathophysiology

2020 Lancet

32. Associations Between Maternal Antenatal Corticosteroid Treatment and Mental and Behavioral Disorders in Children. (Abstract)

Associations Between Maternal Antenatal Corticosteroid Treatment and Mental and Behavioral Disorders in Children. Maternal antenatal corticosteroid treatment is standard care to accelerate fetal maturation when birth before 34 weeks is imminent. Recently, expansion of the indications beyond 34 gestational weeks has been debated. However, data about long-term outcomes remain limited, especially among infants who after treatment exposure are born at term.To study if antenatal corticosteroid (...) December 31, 2017.Maternal antenatal corticosteroid treatment.Primary outcome was any childhood mental and behavioral disorder diagnosed in public specialized medical care settings.Of the 674 877 singleton children born in Finland during the study period, 670 097 were eligible for analysis. The median length of follow-up was 5.8 (interquartile-range, 3.1-8.7) years. Of the 14 868 (2.22%; 46.1% female) corticosteroid treatment-exposed children, 6730 (45.27%) were born at term and 8138 (54.74%) were born

2020 JAMA

33. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. (Abstract)

Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. Primary hemophagocytic lymphohistiocytosis is a rare syndrome characterized by immune dysregulation and hyperinflammation. It typically manifests in infancy and is associated with high mortality.We investigated the efficacy and safety of emapalumab (a human anti-interferon-γ antibody), administered with dexamethasone, in an open-label, single-group, phase 2-3 study involving patients who had received conventional therapy

2020 NEJM

34. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. (Abstract)

Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. A substantial unmet need remains for safe and effective vaccines against dengue virus disease, particularly for individuals who are dengue-naive and those younger than 9 years. We aimed to assess the efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (TAK-003) in healthy children aged 4-16 years.We present data up to 18 months post (...) -vaccination from an ongoing phase 3, randomised, double-blind trial of TAK-003 in endemic regions of Asia and Latin America (26 medical and research centres across Brazil, Colombia, Dominican Republic, Nicaragua, Panama, Philippines, Sri Lanka, and Thailand). Healthy children aged 4-16 years were randomly assigned 2:1 (stratified by age and region) to receive two doses of TAK-003 or two doses of placebo, 3 months apart. Investigators, participants and their parents or guardians, and sponsor

2020 Lancet

35. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. (Abstract)

Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. An unmet clinical need remains for an effective tetravalent dengue vaccine suitable for all age groups, regardless of serostatus. We assessed the immunogenicity and safety of three different dose schedules of a tetravalent dengue vaccine (TAK-003) over a 48-month period in children living in dengue-endemic countries.We did a large, phase 2, double-blind (...) . To maintain masking, TAK-003 recipients were administered placebo doses when appropriate. The primary objective was assessment of neutralising geometric mean titres for each serotype to month 48 assessed in the per-protocol immunogenicity subset. Secondary safety endpoints included proportions of participants with serious adverse events and symptomatic virologically confirmed dengue. This study is registered with ClinicalTrials.gov, NCT02302066.Between Dec 5, 2014, and Feb 13, 2015, 1800 children were

2020 Lancet

36. CAP (children are people too) -support groups for children with family members who has dependency disorders

CAP (children are people too) -support groups for children with family members who has dependency disorders CAP (children are people too) -support groups for children with family members who has dependency disorders We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services CAP (children are people too) -support groups for children with family members who has (...) dependency disorders Share: Reading time approx. 3 minutes “Children are people too (CAP)” addresses children in the age 7–12 who are living with family members who has substance dependency disorder or other dependency problems. The program aims at supporting the children in breaking unhealthy patterns and give them averseness about their own needs and personal borders and raise their self-confidence. Question What scientific studies are there on “Children are people too (CAP)” Identified literature

2020 Swedish Council on Technology Assessement

37. Paediatric multisystem inflammatory syndrome temporally associated with COVID-19

Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 1 Dear Colleagues We are writing to you in regards to a clinical alert published by the Royal College of Paediatrics and child Health on the 1 st of May 2020 highlighting a new COVID-19-associated paediatric hyper-inflammatory presentation (Guidance - Paediatric multisystem inflammatory syndrome temporally associated with COVID-19). Although COVID-19 respiratory presentation in children has been rare, several (...) children have recently presented to hospitals in the South Thames region with the described Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. Many of the children have been severely unwell at presentation requiring resuscitation and transfer to paediatric intensive care. As the anaesthetic team you may be asked to review and assist in their resuscitation and stabilisation. We thought it may be helpful to summarise some of the salient features of the presentation

2020 ICM Anaesthesia COVID-19

38. Evidence summary for spread of COVID-19 by children

was of the infant described above in the case series by Cai et al.. (1) The authors conducted an analysis of the data assuming that asymptomatic children are being mistakenly overlooked as the index case in familial clusters. Using this approach (assuming asymptomatic children as the index case), 21% (6/28) of family clusters would have a paediatric index case. (6) A case series describing the epidemiological and clinical characteristics of 74 children with COVID-19 admitted to two hospitals in China reported (...) -CoV-2 from one of the 10 included children to two family members. This transmission was from a three month old infant to both parents, who developed symptomatic COVID-19 seven days after looking after the infant. (1) A case report of this infant confirms that, at the time of diagnosis, both parents had negative SARS-CoV-2 PCR results. Seven days after Evidence summary of potential for children to contribute to transmission of SARS-CoV-2 Health Information and Quality Authority Page 4 of 14

2020 Health Information and Quality Authority

39. Covid-19: Child Neurology Full Text available with Trip Pro

system dysfunction, a rate that is also lower than that seen in adults. Preschool children and infants were more likely to have severe clinical manifestations than older children. There has been no evidence to date of SARS-Cov-2 involvement in the nervous system in children of any age. Nevertheless, virus infectivity and the severity of the infection represent major alarms for patients affected with chronic (and possibly acute) neurological diseases, including children. Over the last few weeks (...) . However, as reported in literature so far, only a few SARS-Cov-2–positive children have been admitted to paediatric departments and, generally speaking, severe COVID-19 in children is rare. Symptoms can be disparate and designing differentiating clinical criteria aiming to isolate suspected SARS-CoVID-2 children to avoid spreading infection between health care professionals, other patients and visitors is challenging. Some children with an underlying chest condition (eg. cystic fibrosis or severe

2020 European Academy of Neurology

40. The Roles of Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography in the Evaluation and Treatment of Chronic Pancreatitis in Children:A Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutr

drainage. In a child with a very small pancreatic duct diameter in which only a 3-French pancreatic duct stent would be appropriate to place, drainage may be suboptimal because of the small diameter of the stent. Transpapillary stenting of pancreatic fluid collections in children can be a safe and successful treatment (69,74), yet its effectiveness compared with EUS-guided drainage has not been well studied in pediatrics. Overall application of ERCP for pediatric patients with CP to improve symptoms (...) on low to very low quality of evidence, and primarily represent consensus expert opinions. Some of the most urgent issues that need to be addressed relating to advanced endoscopic procedures in children with CP include: 1. Development of equipment allowing for the full breadth of EUS- and ERCP-guided endotherapy across the pediatric age range. 2. Increasing and optimizing the probability that a child undergoing EUS or ERCP is managed by an endoscopist with expertise performing these interventions

2020 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition